Immunogenic
cell death (ICD) is a promising direction of cancer
immunotherapy in hepatocellular carcinoma (HCC). A series of novel
NHC–Au(I) complexes derived from 4,5-diarylimidazole, containing
glycyrrhetinic acid (GA) as an efficient targeting ligand for HCC,
were herein designed and synthesized. Among these, complex 4C exhibited excellent effectiveness for tumor targeting and antitumor
activity, which induced the occurrence of ICD in HCC cells. Additionally, 4C can effectively inhibit TrxR enzyme activity, increase
reactive oxygen species (ROS) expression, lead to redox homeostasis
disorder, mediate mitochondrial dysfunction and endoplasmic reticulum
stress (ERS), and cause the characteristic discharge of damage-associated
molecular patterns (DAMPs) in HCC cells. More importantly, 4C showed a great ICD-inducing effect in a vaccination mouse model
and activated antitumor immunity in a tumor-bearing C57BL/6 mouse
model, which is consistent with the in vitro results.
In conclusion, we found the potential of Au(I) complex with HCC-targeted
capability for effective tumor immunotherapy.